NYSE-listed telehealth provider, Hims & Hers Health Inc, announced in its third quarter 2024 earnings conference call that it plans to bring generic liraglutide to its platform in 2025. The company says it has already confirmed a core supplier and expects to complete test and batch validation over the next few months.
Generic liraglutide products are already approved in the US, EU, UK and India, and are under consideration in Australia.
Originator Novo Nordisk supplies liraglutide as Victoza® and Saxenda®.